LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

Home・Akcijų sąrašas・Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals Inc

Uždarymo kaina

1.18 -0.84

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.16

Max

1.18

Pagrindiniai rodikliai
By Trading Economics
Pajamos	1.7M -5.1M
Pardavimai	90K 90K
Pelno marža	-5,701.111
Darbuotojai	25
EBITDA	2.6M -4.9M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+408.47% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-03-27

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-5.9M 36M
Ankstesnė atidarymo kaina	2.02
Ankstesnė uždarymo kaina	1.18

Actinium Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-06 19:32; UTC

Įsigijimai, susijungimai, perėmimai

Diana Shipping Increases Offer to Acquire Genco -- Update

2026-03-06 17:44; UTC

Įsigijimai, susijungimai, perėmimai

Lonza to Offload Majority Stake in Capsule Business to Lone Star in $2.2 Billion Deal

2026-03-06 22:26; UTC

Svarbiausios naujienos

Why $100 Oil Is Now in Sight. Who Wins, Who Loses. -- Barrons.com

2026-03-06 22:07; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Boeing Says Spirit Acquisition Will Help Improve Safety -- Market Talk

2026-03-06 22:03; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-03-06 22:03; UTC

Rinkos pokalbiai

Boeing CEO's Pay Nears $24 Million During Recovery Phase -- Market Talk

2026-03-06 21:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Financial Services Roundup: Market Talk

2026-03-06 21:37; UTC

Uždarbis

Salesforce Stock Might Not Be an AI Loser After All -- Barrons.com

2026-03-06 21:25; UTC

Svarbiausios naujienos

How The Iran War Impacts Ukraine. -- Barrons.com

2026-03-06 21:17; UTC

Uždarbis

Burlington Stores' Strong Year Should Lift the Stock. What Comes Next. -- Barrons.com

2026-03-06 20:50; UTC

Uždarbis

Marvell Stock Pops 20%. Semiconductor Earnings Show AI Demand Is Strong. -- Barrons.com

2026-03-06 20:46; UTC

Uždarbis

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

2026-03-06 20:31; UTC

Svarbiausios naujienos

Oil Prices Soar Past $90. Trump Demands 'Unconditional Surrender' From Iran -- and Kuwait Cut Production. -- Barrons.com

2026-03-06 20:18; UTC

Rinkos pokalbiai

Oil Makes Record Weekly Gains As Strait of Hormuz Stays Shut -- Market Talk

2026-03-06 20:12; UTC

Rinkos pokalbiai

Svarbiausios naujienos

U.S. Natural Gas Futures Gain on Global Energy Turmoil -- Market Talk

2026-03-06 19:10; UTC

Rinkos pokalbiai

Svarbiausios naujienos

$150 Oil Seen As Realistic If Hormuz Closure Lasts -- Market Talk

2026-03-06 18:54; UTC

Rinkos pokalbiai

Fed's Hammack: Dollar Hasn't Lost Prime Status -- Market Talk

2026-03-06 18:44; UTC

Rinkos pokalbiai

Svarbiausios naujienos

U.S. Oil Rig Count Increases By 4 to 411 -- Market Talk

2026-03-06 18:08; UTC

Uždarbis

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

2026-03-06 18:04; UTC

Uždarbis

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

2026-03-06 18:04; UTC

Uždarbis

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

2026-03-06 17:49; UTC

Rinkos pokalbiai

AI-Driven Picks-And-Shovels Bet Comes With Risks -- Market Talk

2026-03-06 17:46; UTC

Svarbiausios naujienos

Kuwait Cuts Oil Production as Fallout From Iran Conflict Intensifies -- Update

2026-03-06 17:40; UTC

Rinkos pokalbiai

Uždarbis

Marvell's Long-Term Outlook Well-Received By Investors -- Market Talk

2026-03-06 17:40; UTC

Uždarbis

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

2026-03-06 17:32; UTC

Rinkos pokalbiai

Svarbiausios naujienos

No Quick Solution for Hormuz Shipping as U.S. Oil Tops $90 -- Market Talk

2026-03-06 17:28; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Aluminum Rising as Strait of Hormuz Stays Locked -- Market Talk

2026-03-06 17:20; UTC

Rinkos pokalbiai

Uždarbis

Auto & Transport Roundup: Market Talk

2026-03-06 17:20; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Basic Materials Roundup: Market Talk

2026-03-06 17:20; UTC

Įsigijimai, susijungimai, perėmimai

BlackRock Sticks to Redemption Minimum on Credit Fund, Sends Shares Lower -- WSJ

Akcijų palyginimas

Kainos pokytis

Actinium Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

408.47% į viršų

12 mėnesių prognozė

Vidutinis 6 USD 408.47%

Aukščiausias 9 USD

Žemiausias 4 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Actinium Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

3 ratings

Pirkti

Laikyti

Parduoti

Remiantis 3 analitikų, pateikusių Actinium Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.